Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 0.42 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.41 |
| ▸ | NT5M | Q9NPB1 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6066040 | 0.92 | TK1 (0.45) | TK1RNASE1NT5M | |
| SCHEMBL2113755 | 0.88 | TK1 (0.42) | TK1RNASE1NT5MBCHE | |
| SCHEMBL7535867 | 0.84 | TK1 (0.52) | TK1 | |
| SCHEMBL9564565 | 0.84 | TK1 (0.52) | TK1 | |
| SCHEMBL60737 | 0.84 | TK1 (0.52) | TK1 | |
| SCHEMBL8999406 | 0.83 | TK1 (0.45) | TK1RNASE1NT5M | |
| SCHEMBL8426287 | 0.83 | TK1 (0.45) | TK1RNASE1NT5M | |
| SCHEMBL8931988 | 0.83 | RNASE1 (0.42) | TK1RNASE1NT5M | |
| SCHEMBL4580937 | 0.82 | NT5M (0.41) | TK1RNASE1NT5M | |
| SCHEMBL2112758 | 0.81 | TYMP (0.40) | TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158770-B2 | Content dependent inhibitors of cytidine deaminases and uses thereof | UNIVERSITY OF ROCHESTER (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090099105-A1 | Content dependent inhibitors of cytidine deaminases and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-04-16 | — | — | US | disclosed |
| US-5677439-A | PREVENTION GENE EXPRESSION | SANOFI (FR) | 1997-10-14 | — | — | US | disclosed |
| EP-0541722-B1 | COMPOUNDS AND METHODS FOR INHIBITING GENE EXPRESSION | STERLING WINTHROP INC (US) | 1995-12-20 | — | — | EP | disclosed |
| EP-0541722-A1 | COMPOUNDS AND METHODS FOR INHIBITING GENE EXPRESSION. | STERLING WINTHROP INC (US) | 1993-05-19 | — | — | EP | disclosed |
| WO-1992002534-A2 | COMPOUNDS AND METHODS FOR INHIBITING GENE EXPRESSION | STERLING DRUG, INC. (US) | 1992-02-20 | — | — | WO | disclosed |
| EP-0040099-A1 | Polynucleotide synthesis | ens BIO LOGICALS INC. (CA) | 1981-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099105-A1 | Content dependent inhibitors of cytidine deaminases and uses thereof | DCTD, CDA, ADA | TK1 178/4885RNASE1 133/4885NT5M 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.